HealthWall Street Journalabout 3 hours ago
Merck Acquires U.K. Biotech Silence for $1.3B
2 min read
Germany's Merck KGaA agreed to acquire U.K. biotech Silence Therapeutics for about $1.3 billion in cash. The deal adds divesiran, an experimental medicine for polycythemia vera, to Merck's pipeline and is slated to wrap up during the first three months of 2027.
Level
Hype check
Tap to vote and see what everyone thinks.